AI assistant
PFIZER INC — Director's Dealing 2018
Feb 28, 2018
29831_dirs_2018-02-27_843023a0-6c84-4ad1-985f-fb68679c263b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2018-02-24
Reporting Person: READ IAN C (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-02-24 | Common Stock | M | 483559.0000 | $18.9000 | Acquired | 1140007.0000 | Direct |
| 2018-02-24 | Common Stock | M | 420000.0000 | $20.9000 | Acquired | 1560007.0000 | Direct |
| 2018-02-24 | Common Stock | F | 126006.0000 | $36.2600 | Disposed | 1434001.0000 | Direct |
| 2018-02-24 | Common Stock | F | 154058.0000 | $36.2600 | Disposed | 1279943.0000 | Direct |
| 2018-02-24 | Common Stock | F | 154289.0000 | $35.9800 | Disposed | 1125654.0000 | Direct |
| 2018-02-24 | Common Stock | F | 157353.0000 | $35.9800 | Disposed | 968301.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-24 | Stock Appreciation Rights | $20.9000 | M | 420000.0000 | Disposed | 2018-02-24 | Common Stock (420000.0000) | Direct |
| 2018-02-24 | Stock Appreciation Rights | $18.9000 | M | 483559.0000 | Disposed | 2018-02-24 | Common Stock (483559.0000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 11075.0000 | Indirect |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: Price is the closing price of Pfizer common stock on February 23, 2018
F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.